Citius Pharmaceuticals, Inc.

CTXR · NASDAQ
Analyze with AI
9/30/2025
9/30/2024
9/30/2023
9/30/2022
Operating Activities
Net Income-$39,740-$39,426-$32,543-$33,641
Dep. & Amort.$214$210$194$180
Deferred Tax$1,057$576$576$576
Stock-Based Comp.$10,836$11,840$6,617$3,906
Change in WC$0-$1,685-$4,006$240
Other Non-Cash$1,080$284$102$378
Operating Cash Flow-$26,553-$28,201-$29,060-$28,361
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.-$5,750-$5,000$0$0
Investing Cash Flow-$5,750-$5,000$0$0
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$27$13,804$13,798$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$33,303-$3,831$31$0
Financing Cash Flow$33,303$9,972$13,829$0
Forex Effect$0$0$0$0
Net Chg. in Cash$1,000-$23,229-$15,231-$28,361
Supplemental Information
Beg. Cash$3,252$26,481$41,712$70,073
End Cash$4,252$3,252$26,481$41,712
Free Cash Flow-$26,553-$28,201-$29,060-$28,361
Citius Pharmaceuticals, Inc. (CTXR) Financial Statements & Key Stats | AlphaPilot